×
News Home

Is LogicBio Therapeutics Inc (LOGC) a Winner in the Biotechnology Industry?

Wednesday, October 05, 2022 01:35 PM | InvestorsObserver Analysts
Is LogicBio Therapeutics Inc (LOGC) a Winner in the Biotechnology Industry?

LogicBio Therapeutics Inc (LOGC) is near the top in its industry group according to InvestorsObserver. LOGC gets an overall rating of 96. That means it scores higher than 96 percent of stocks. LogicBio Therapeutics Inc gets a 100 rank in the Biotechnology industry. Biotechnology is number 15 out of 148 industries.

Overall Score - 96
LOGC has an Overall Score of 96. Find out what this means to you and get the rest of the rankings on LOGC!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With LogicBio Therapeutics Inc Stock Today?

LogicBio Therapeutics Inc (LOGC) stock has risen 0.25% while the S&P 500 is down -0.3% as of 1:34 PM on Wednesday, Oct 5. LOGC has risen $0.01 from the previous closing price of $2.02 on volume of 566,298 shares. Over the past year the S&P 500 is lower by -13.03% while LOGC is down -53.12%. LOGC lost -$0.16 per share the over the last 12 months. Click Here to get the full Stock Report for LogicBio Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App